数据中心
龙虎榜
大单追踪
资金流向
业绩预告
新股申购
行情中心
沪深市场
香港市场
美国市场
全球市场
行业风云
全球市场
向上 向下

董事介绍

注:董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Amy Schulman Director 58 30.87万美元 未持股 2019-02-28
Kevin Churchwell Director 57 未披露 未持股 2019-02-28
George Conrades Director 80 未披露 未持股 2019-02-28
Marsha Fanucci Director 65 未披露 未持股 2019-02-28
Ole Isacson Director 59 未披露 未持股 2019-02-28
Stephanie Lovell Director 59 未披露 未持股 2019-02-28
Terrance McGuire Director 62 31.14万美元 未持股 2019-02-28
Michael Mendelsohn Director 63 未披露 未持股 2019-02-28
Peter M. Hecht Chief Executive Officer and Director 55 516.01万美元 未持股 2019-02-28
Marsha H. Fanucci Director 65 31.14万美元 未持股 2019-02-28

高管介绍

注:高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Mark G. Currie -- President 64 未披露 未持股 2019-02-28
William Huyett Chief Financial Officer 63 414.23万美元 未持股 2019-02-28
Peter M. Hecht Chief Executive Officer and Director 55 516.01万美元 未持股 2019-02-28
Mark G. Currie President 64 244.54万美元 未持股 2019-02-28

董事简历

中英对照 |  中文 |  英文
Amy Schulman

Amy Schulman自2014年起担任公司董事。Amy是Arsia Therapeutics(Polaris Partners一家投资合伙公司)首席执行官,以及Harvard Business School高级讲师。Alnylam Pharmaceuticals 和 Bind Therapeutics董事。之前Amy曾于2008年到2013年担任 Pfizer执行副总裁和总法律顾问;2012年到2013年担任 Pfizer的消费者保健业务集团主管。在此之前,她从1998年到2008年担任 DLA Piper合伙人。她持有Yale Law School法律博士学位以及Wesleyan University文学学士学位。Amy还担任The Brookings Institution 以及 Wesleyan University信托董事会成员。


Amy Schulman has served as a member of our board of directors since February 2015. She joined in July 2014 as an Entrepreneur Partner at Polaris Partners, a venture capital firm, and she served as CEO of Arsia Therapeutics, a Polaris-backed company, from July 2014 until its acquisition by Eagle Pharmaceuticals in November 2016. She served as director of Bind Therapeutics from September 2014 to June 2016. In July 2015 Ms. Schulman co-founded Lyndra, where she currently serves as CEO, and since January 2017 she has served as CEO of Olivo Laboratories, which sold its cosmetic assets to Shiseido in January 2018. She serves as the Executive Chair of SQZ Biotech and Suono Bio. Ms. Schulman currently serves on the boards of directors of Alnylam Pharmaceuticals, a publicly traded biopharmaceutical company, where she has served since July 2014; Ironwood Pharmaceuticals, Inc., a publicly traded drug manufacturer, where she has served since January 2017; and Blue Buffalo Pet Products, Inc., a publicly traded pet food company, where she has served since 2014. In addition, she serves as a director of the Whitehead Institute. She is a member of Harvard Business School’s Faculty where she serves as a Senior Lecturer and teaches legal and corporate accountability. A Phi Beta Kappa graduate of Wesleyan University, Ms. Schulman earned her J.D. from Yale Law School in 1989.
Amy Schulman自2014年起担任公司董事。Amy是Arsia Therapeutics(Polaris Partners一家投资合伙公司)首席执行官,以及Harvard Business School高级讲师。Alnylam Pharmaceuticals 和 Bind Therapeutics董事。之前Amy曾于2008年到2013年担任 Pfizer执行副总裁和总法律顾问;2012年到2013年担任 Pfizer的消费者保健业务集团主管。在此之前,她从1998年到2008年担任 DLA Piper合伙人。她持有Yale Law School法律博士学位以及Wesleyan University文学学士学位。Amy还担任The Brookings Institution 以及 Wesleyan University信托董事会成员。
Amy Schulman has served as a member of our board of directors since February 2015. She joined in July 2014 as an Entrepreneur Partner at Polaris Partners, a venture capital firm, and she served as CEO of Arsia Therapeutics, a Polaris-backed company, from July 2014 until its acquisition by Eagle Pharmaceuticals in November 2016. She served as director of Bind Therapeutics from September 2014 to June 2016. In July 2015 Ms. Schulman co-founded Lyndra, where she currently serves as CEO, and since January 2017 she has served as CEO of Olivo Laboratories, which sold its cosmetic assets to Shiseido in January 2018. She serves as the Executive Chair of SQZ Biotech and Suono Bio. Ms. Schulman currently serves on the boards of directors of Alnylam Pharmaceuticals, a publicly traded biopharmaceutical company, where she has served since July 2014; Ironwood Pharmaceuticals, Inc., a publicly traded drug manufacturer, where she has served since January 2017; and Blue Buffalo Pet Products, Inc., a publicly traded pet food company, where she has served since 2014. In addition, she serves as a director of the Whitehead Institute. She is a member of Harvard Business School’s Faculty where she serves as a Senior Lecturer and teaches legal and corporate accountability. A Phi Beta Kappa graduate of Wesleyan University, Ms. Schulman earned her J.D. from Yale Law School in 1989.
Kevin Churchwell

分离完成后,Kevin Churchwell将担任我们的董事会成员。Churchwell博士自2018年9月起担任波士顿儿童医院院长,自2013年8月起担任波士顿儿童医院卫生事务执行Vice President兼首席运营官。加入Boston Children’s Hospital之前,Churchwell博士从2010年11月到2013年7月是Nemours/Alfred I.DuPont Hospital for Children的首席执行官。在此之前,Churchwell博士是The Monroe Carrell Jr.的首席执行官兼执行董事。Children’s Hospital,范德堡大学医学中心的一部分,2007年7月至2010年10月。Churchwell博士从1993年开始一直担任范德堡大学医学中心波士顿儿童医院(Boston Children’s Hospital,Vanderbilt University Medical Center)的临床医师与教员,最近被任命为哈佛医学院(Harvard Medical School)的罗伯特与戴娜史密斯(Robert and Dana Smith)麻醉副教授。Churchwell毕业于Massachusetts Institute of Technology生物学B.S.,在Vanderbilt Medical School获得医学博士学位。


Kevin Churchwell will serve as a member of our board of directors upon completion of this separation. Dr. Churchwell has been the President of Boston Children's Hospital since September of 2018 and executive vice president of health affairs and chief operating officer at Boston Children's Hospital since August of 2013. Before joining Boston Children's Hospital, Dr. Churchwell was the chief executive officer of Nemours/Alfred I. duPont Hospital for Children from November 2010 to July 2013. Prior to that, Dr. Churchwell was the chief executive officer and executive director for the Monroe Carrell Jr. Children's Hospital, part of the Vanderbilt University Medical Center, from July 2007 to October 2010. Since 1993 Dr. Churchwell has been a clinician and faculty member at Boston Children's Hospital, Vanderbilt University Medical Center and was recently appointed the Robert and Dana Smith Associate Professor of Anesthesia at Harvard Medical School.Dr. Churchwell graduated with a B.S in Biology from the Massachusetts Institute of Technology and received his M.D. from Vanderbilt Medical School.
分离完成后,Kevin Churchwell将担任我们的董事会成员。Churchwell博士自2018年9月起担任波士顿儿童医院院长,自2013年8月起担任波士顿儿童医院卫生事务执行Vice President兼首席运营官。加入Boston Children’s Hospital之前,Churchwell博士从2010年11月到2013年7月是Nemours/Alfred I.DuPont Hospital for Children的首席执行官。在此之前,Churchwell博士是The Monroe Carrell Jr.的首席执行官兼执行董事。Children’s Hospital,范德堡大学医学中心的一部分,2007年7月至2010年10月。Churchwell博士从1993年开始一直担任范德堡大学医学中心波士顿儿童医院(Boston Children’s Hospital,Vanderbilt University Medical Center)的临床医师与教员,最近被任命为哈佛医学院(Harvard Medical School)的罗伯特与戴娜史密斯(Robert and Dana Smith)麻醉副教授。Churchwell毕业于Massachusetts Institute of Technology生物学B.S.,在Vanderbilt Medical School获得医学博士学位。
Kevin Churchwell will serve as a member of our board of directors upon completion of this separation. Dr. Churchwell has been the President of Boston Children's Hospital since September of 2018 and executive vice president of health affairs and chief operating officer at Boston Children's Hospital since August of 2013. Before joining Boston Children's Hospital, Dr. Churchwell was the chief executive officer of Nemours/Alfred I. duPont Hospital for Children from November 2010 to July 2013. Prior to that, Dr. Churchwell was the chief executive officer and executive director for the Monroe Carrell Jr. Children's Hospital, part of the Vanderbilt University Medical Center, from July 2007 to October 2010. Since 1993 Dr. Churchwell has been a clinician and faculty member at Boston Children's Hospital, Vanderbilt University Medical Center and was recently appointed the Robert and Dana Smith Associate Professor of Anesthesia at Harvard Medical School.Dr. Churchwell graduated with a B.S in Biology from the Massachusetts Institute of Technology and received his M.D. from Vanderbilt Medical School.
George Conrades

分离完成后,George Conrades将担任我们的董事会成员。Conrades先生自2018年6月起担任阿卡迈技术有限公司(Akamai)的执行顾问。此前,Conrades先生于2010年8月至2018年3月担任Akamai的董事长,并于2005年至2010年担任执行主席。Conrades先生于1999年至2005年担任Akamai的董事长兼首席执行官,并于1998年至2018年3月担任董事。他一直担任Longfellow Venture Partners公司的管理合伙人(2009年7月以来),也曾担任Polaris Venture Partners公司的风险合伙人(从1998年到2012年),在那里他现在担任荣誉合伙人。从1997年到1998年,Conrades先生担任GTE的执行Vice President和GTE Intemetwork的总裁。Conrades从1994年到1997年被GTE Intemetwork收购担任BBN Corporation首席执行官。在加入BBN公司之前,Conrades先生是国际商业机器公司(IBM)的高级副总裁,也是IBM公司管理委员会的成员。Conrades先生自2008年起担任甲骨文股份有限公司董事,并于2002年至2016年4月担任Harley Davidson,Inc.董事。Conrades先生此前曾于2005年至2016年4月担任Ironwood董事。此外,Conrades先生目前担任俄亥俄州卫斯理大学(Ohio Wesleyan University)董事会的终身受托人。Conrades在Ohio Wesleyan University获得物理和数学学士学位,在University of Chicago获得工商管理硕士学位。


George Conrades will serve as a member of our board of directors upon completion of this separation. Mr. Conrades has served as an executive advisor to Akamai Technologies, Inc., or Akamai, since June 2018. Previously, Mr. Conrades was the chairman of Akamai from August 2010 until March 2018 and executive chairman from 2005 to 2010. Mr. Conrades was both chairman and chief executive officer of Akamai from 1999 to 2005 and served as a director from 1998 to March 2018. Mr. Conrades has been a managing partner at Longfellow Venture Partners since July 2009 and was a venture partner of Polaris Venture Partners from 1998 to 2012 where he is now partner emeritus. From 1997 to 1998 Mr. Conrades served as executive vice president of GTE and president of GTE Intemetworking. Mr. Conrades served as chief executive officer of BBN Corporation from 1994 until its acquisition by GTE Intemetworking in 1997. Prior to joining BBN Corporation, Mr. Conrades was a senior vice president at International Business Machines Corporation, or IBM, and a member of IBM's corporate management board. Mr. Conrades has served as a director of Oracle Corporation since 2008 and was a director of Harley Davidson, Inc. from 2002 to April 2016. Mr. Conrades previously served as a director of Ironwood from 2005 until April 2016. Additionally, Mr. Conrades currently serves as life trustee on the board of Ohio Wesleyan University.Mr. Conrades received a B.A. in physics and math from Ohio Wesleyan University and an M.B.A. from the University of Chicago.
分离完成后,George Conrades将担任我们的董事会成员。Conrades先生自2018年6月起担任阿卡迈技术有限公司(Akamai)的执行顾问。此前,Conrades先生于2010年8月至2018年3月担任Akamai的董事长,并于2005年至2010年担任执行主席。Conrades先生于1999年至2005年担任Akamai的董事长兼首席执行官,并于1998年至2018年3月担任董事。他一直担任Longfellow Venture Partners公司的管理合伙人(2009年7月以来),也曾担任Polaris Venture Partners公司的风险合伙人(从1998年到2012年),在那里他现在担任荣誉合伙人。从1997年到1998年,Conrades先生担任GTE的执行Vice President和GTE Intemetwork的总裁。Conrades从1994年到1997年被GTE Intemetwork收购担任BBN Corporation首席执行官。在加入BBN公司之前,Conrades先生是国际商业机器公司(IBM)的高级副总裁,也是IBM公司管理委员会的成员。Conrades先生自2008年起担任甲骨文股份有限公司董事,并于2002年至2016年4月担任Harley Davidson,Inc.董事。Conrades先生此前曾于2005年至2016年4月担任Ironwood董事。此外,Conrades先生目前担任俄亥俄州卫斯理大学(Ohio Wesleyan University)董事会的终身受托人。Conrades在Ohio Wesleyan University获得物理和数学学士学位,在University of Chicago获得工商管理硕士学位。
George Conrades will serve as a member of our board of directors upon completion of this separation. Mr. Conrades has served as an executive advisor to Akamai Technologies, Inc., or Akamai, since June 2018. Previously, Mr. Conrades was the chairman of Akamai from August 2010 until March 2018 and executive chairman from 2005 to 2010. Mr. Conrades was both chairman and chief executive officer of Akamai from 1999 to 2005 and served as a director from 1998 to March 2018. Mr. Conrades has been a managing partner at Longfellow Venture Partners since July 2009 and was a venture partner of Polaris Venture Partners from 1998 to 2012 where he is now partner emeritus. From 1997 to 1998 Mr. Conrades served as executive vice president of GTE and president of GTE Intemetworking. Mr. Conrades served as chief executive officer of BBN Corporation from 1994 until its acquisition by GTE Intemetworking in 1997. Prior to joining BBN Corporation, Mr. Conrades was a senior vice president at International Business Machines Corporation, or IBM, and a member of IBM's corporate management board. Mr. Conrades has served as a director of Oracle Corporation since 2008 and was a director of Harley Davidson, Inc. from 2002 to April 2016. Mr. Conrades previously served as a director of Ironwood from 2005 until April 2016. Additionally, Mr. Conrades currently serves as life trustee on the board of Ohio Wesleyan University.Mr. Conrades received a B.A. in physics and math from Ohio Wesleyan University and an M.B.A. from the University of Chicago.
Marsha Fanucci

Marsha Fanucci自2014年10月以来一直是我们的董事会成员。自2009年以来,Fanucci女士一直是私人和公开交易的生物技术公司的独立顾问。从2004年到2009年,她曾担任Millennium Pharmaceuticals公司(生物制药公司,随后被Takeda Pharmaceuticals公司收购)的高级副总裁兼首席财务官。在过去五年中,Fanucci女士曾担任AlnylamPharmaceuticals,Inc.、IronwoodPharmaceuticals,Inc.、CyclerionTherapeutics,Inc.等多家上市公司的董事会成员。B.MomentaPharmaceuticals,Inc.和SyrosPharmaceuticals,Inc.Fanucci女士拥有西弗吉尼亚大学(West Virginia University)的药学学士学位和东北大学(Northeastern University)的工商管理硕士学位。


Marsha Fanucci has been a member of our board of directors since October 2014. Since 2009 Ms. Fanucci has been an independent consultant for private and publicly traded biotechnology companies. From 2004 through 2009 she served as Senior Vice President and Chief Financial Officer of Millennium Pharmaceuticals, Inc., a biopharmaceutical company that was subsequently acquired by Takeda Pharmaceuticals. During the past five years, Ms. Fanucci has served as a member of the boards of directors of various publicly traded companies, including Alnylam Pharmaceuticals, Inc., Ironwood Pharmaceuticals, Inc., Cyclerion Therapeutics, Inc. Momenta Pharmaceuticals, Inc. and Syros Pharmaceuticals, Inc. Ms. Fanucci holds a B.S. in pharmacy from West Virginia University and her M.B.A. from Northeastern University.
Marsha Fanucci自2014年10月以来一直是我们的董事会成员。自2009年以来,Fanucci女士一直是私人和公开交易的生物技术公司的独立顾问。从2004年到2009年,她曾担任Millennium Pharmaceuticals公司(生物制药公司,随后被Takeda Pharmaceuticals公司收购)的高级副总裁兼首席财务官。在过去五年中,Fanucci女士曾担任AlnylamPharmaceuticals,Inc.、IronwoodPharmaceuticals,Inc.、CyclerionTherapeutics,Inc.等多家上市公司的董事会成员。B.MomentaPharmaceuticals,Inc.和SyrosPharmaceuticals,Inc.Fanucci女士拥有西弗吉尼亚大学(West Virginia University)的药学学士学位和东北大学(Northeastern University)的工商管理硕士学位。
Marsha Fanucci has been a member of our board of directors since October 2014. Since 2009 Ms. Fanucci has been an independent consultant for private and publicly traded biotechnology companies. From 2004 through 2009 she served as Senior Vice President and Chief Financial Officer of Millennium Pharmaceuticals, Inc., a biopharmaceutical company that was subsequently acquired by Takeda Pharmaceuticals. During the past five years, Ms. Fanucci has served as a member of the boards of directors of various publicly traded companies, including Alnylam Pharmaceuticals, Inc., Ironwood Pharmaceuticals, Inc., Cyclerion Therapeutics, Inc. Momenta Pharmaceuticals, Inc. and Syros Pharmaceuticals, Inc. Ms. Fanucci holds a B.S. in pharmacy from West Virginia University and her M.B.A. from Northeastern University.
Ole Isacson

分离完成后,Ole Isacson将担任我们的董事会成员。Isacson博士从2002年开始一直担任哈佛医学院(Harvard Medical School)的神经学与神经科学教授。在担任现职之前,Isacson博士曾在哈佛医学院(Harvard Medical School)担任多个学术职位。自2005年成立以来,Isacson博士一直担任哈佛干细胞研究所(Harvard Stem Cell Institute)的主要教员,并且是McLean Hospital神经再生研究所的创始董事,在那里他自2010年以来一直担任董事。2016年9月至2017年5月,艾萨克森博士担任辉瑞公司神经科学与疼痛全球研发部门的首席科学官兼高级副总裁。Isacson在瑞典隆德大学(University of Lund)获得医学学士和医学博士学位。


Ole Isacson will serve as a member of our board of directors upon completion of this separation. Dr. Isacson has been professor of neurology and neuroscience at Harvard Medical School since 2002. Prior to his current role, Dr. Isacson served in a number of academic roles at Harvard Medical School. Since its founding in 2005 Dr. Isacson has been principal faculty of the Harvard Stem Cell Institute and is the founding director of the Neuroregeneration Institute at McLean Hospital, where he has served as a director since 2010. From September 2016 to May 2017 Dr. Isacson was the chief scientific officer and senior vice president for Pfizer Inc.'s Neuroscience and Pain Worldwide R&D division.Dr. Isacson received his Medical Bachelor and Doctor of Medicine degrees from the University of Lund in Sweden.
分离完成后,Ole Isacson将担任我们的董事会成员。Isacson博士从2002年开始一直担任哈佛医学院(Harvard Medical School)的神经学与神经科学教授。在担任现职之前,Isacson博士曾在哈佛医学院(Harvard Medical School)担任多个学术职位。自2005年成立以来,Isacson博士一直担任哈佛干细胞研究所(Harvard Stem Cell Institute)的主要教员,并且是McLean Hospital神经再生研究所的创始董事,在那里他自2010年以来一直担任董事。2016年9月至2017年5月,艾萨克森博士担任辉瑞公司神经科学与疼痛全球研发部门的首席科学官兼高级副总裁。Isacson在瑞典隆德大学(University of Lund)获得医学学士和医学博士学位。
Ole Isacson will serve as a member of our board of directors upon completion of this separation. Dr. Isacson has been professor of neurology and neuroscience at Harvard Medical School since 2002. Prior to his current role, Dr. Isacson served in a number of academic roles at Harvard Medical School. Since its founding in 2005 Dr. Isacson has been principal faculty of the Harvard Stem Cell Institute and is the founding director of the Neuroregeneration Institute at McLean Hospital, where he has served as a director since 2010. From September 2016 to May 2017 Dr. Isacson was the chief scientific officer and senior vice president for Pfizer Inc.'s Neuroscience and Pain Worldwide R&D division.Dr. Isacson received his Medical Bachelor and Doctor of Medicine degrees from the University of Lund in Sweden.
Stephanie Lovell

分离完成后,Stephanie Lovell将担任我们的董事会成员。Lovell女士自2015年7月起担任马萨诸塞州蓝十字蓝盾(Blue Cross Blue Shield of Massachusetts,Inc.,简称BCBSMA)的执行Vice President、医疗保险和首席法律官。Lovell女士此前曾于2011年12月至2015年7月担任BCBSMA的高级副总裁and General Counsel。加入BCBSMA之前,Lovell从2007年3月到2011年12月担任Boston Medical Center行政and General Counsel高级副总裁。她此前也曾担任the Massachusetts Office of the Attorney的首席助理司法部长,以及the Massachusetts State Ethics Commission的执行董事。Lovell女士目前担任新英格兰法律基金会(New England Law Foundation)和合伙企业(Partnership,Inc.)的董事,并担任马萨诸塞州纳税人基金会(Massachusetts纳税人基金会)的受托人。她也是波士顿律师基金会(Boston Bar Foundation)的赠款委员会主席,也是Goodwill Industries of Massachusetts的投资委员会成员。Lovell在Hamilton College获得哲学学士学位,在Boston University School of Law获得法学博士学位。


Stephanie Lovell will serve as a member of our board of directors upon completion of this separation. Ms. Lovell has served as the executive vice president, Medicare and chief legal officer for Blue Cross Blue Shield of Massachusetts, Inc., or BCBSMA, since July 2015. Ms. Lovell previously served as the senior vice president and general counsel of BCBSMA from December 2011 to July 2015. Prior to BCBSMA, Ms. Lovell was the senior vice president of administration and general counsel for Boston Medical Center from March 2007 to December 2011. She also previously served as the first assistant attorney general in the Massachusetts Office of the Attorney General and as the executive director for the Massachusetts State Ethics Commission. Ms. Lovell currently serves as a director of the New England Law Foundation and The Partnership, Inc., and as a trustee of the Massachusetts Taxpayers Foundation. She also chairs the grants committee of the Boston Bar Foundation and is a member of the investment committee of Goodwill Industries of Massachusetts.Ms. Lovell received a B.A. in philosophy from Hamilton College and a J.D. from Boston University School of Law.
分离完成后,Stephanie Lovell将担任我们的董事会成员。Lovell女士自2015年7月起担任马萨诸塞州蓝十字蓝盾(Blue Cross Blue Shield of Massachusetts,Inc.,简称BCBSMA)的执行Vice President、医疗保险和首席法律官。Lovell女士此前曾于2011年12月至2015年7月担任BCBSMA的高级副总裁and General Counsel。加入BCBSMA之前,Lovell从2007年3月到2011年12月担任Boston Medical Center行政and General Counsel高级副总裁。她此前也曾担任the Massachusetts Office of the Attorney的首席助理司法部长,以及the Massachusetts State Ethics Commission的执行董事。Lovell女士目前担任新英格兰法律基金会(New England Law Foundation)和合伙企业(Partnership,Inc.)的董事,并担任马萨诸塞州纳税人基金会(Massachusetts纳税人基金会)的受托人。她也是波士顿律师基金会(Boston Bar Foundation)的赠款委员会主席,也是Goodwill Industries of Massachusetts的投资委员会成员。Lovell在Hamilton College获得哲学学士学位,在Boston University School of Law获得法学博士学位。
Stephanie Lovell will serve as a member of our board of directors upon completion of this separation. Ms. Lovell has served as the executive vice president, Medicare and chief legal officer for Blue Cross Blue Shield of Massachusetts, Inc., or BCBSMA, since July 2015. Ms. Lovell previously served as the senior vice president and general counsel of BCBSMA from December 2011 to July 2015. Prior to BCBSMA, Ms. Lovell was the senior vice president of administration and general counsel for Boston Medical Center from March 2007 to December 2011. She also previously served as the first assistant attorney general in the Massachusetts Office of the Attorney General and as the executive director for the Massachusetts State Ethics Commission. Ms. Lovell currently serves as a director of the New England Law Foundation and The Partnership, Inc., and as a trustee of the Massachusetts Taxpayers Foundation. She also chairs the grants committee of the Boston Bar Foundation and is a member of the investment committee of Goodwill Industries of Massachusetts.Ms. Lovell received a B.A. in philosophy from Hamilton College and a J.D. from Boston University School of Law.
Terrance McGuire

Terrance McGuire自2017年12月以来一直担任我们的董事会成员。McGuire先生担任Polaris Partners的普通合伙人,这是一家他于1996年联合创立的风险投资公司。他目前任职于Alector,Inc.和Cyclerion公司的董事会,此前曾任职于Acceleron Pharma公司、Arsanis公司、IronwoodPharmaceuticals,Inc.公司和Pulmatrix,Inc.公司的董事会。McGuire先生还担任麻省理工学院(Massachusetts Institute of Technology)David H.Koch综合癌症研究所的董事会成员,哈佛商学院Arthur Rock创业中心和梦百合倡议咨询委员会以及达特茅斯学院Thayer工程学院顾问委员会。McGuire先生拥有霍巴特学院(Hobart College)的物理学和经济学学士学位,达特茅斯学院(Thayer School at Dartmouth College)的工程学硕士学位和哈佛商学院(Harvard Business School)的工商管理硕士学位。


Terrance McGuire has served as a member of our board of directors since December 2017. Mr. McGuire serves as a General Partner of Polaris Partners, a venture capital firm he co-founded in 1996. He currently serves on the board of directors of Alector, Inc. and Cyclerion, Inc., and previously served on the board of directors of Acceleron Pharma, Inc., Arsanis, Inc., Ironwood Pharmaceuticals, Inc. and Pulmatrix, Inc. Mr. McGuire also serves as a member of the board of The David H. Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology, The Arthur Rock Center for Entrepreneurship at Harvard Business School and The Healthcare Initiative Advisory Board and on the Board of Advisors of the Thayer School of Engineering at Dartmouth College. Mr. McGuire holds a B.S. in Physics and Economics from Hobart College, an M.S. in Engineering from the Thayer School at Dartmouth College and an M.B.A. from Harvard Business School.
Terrance McGuire自2017年12月以来一直担任我们的董事会成员。McGuire先生担任Polaris Partners的普通合伙人,这是一家他于1996年联合创立的风险投资公司。他目前任职于Alector,Inc.和Cyclerion公司的董事会,此前曾任职于Acceleron Pharma公司、Arsanis公司、IronwoodPharmaceuticals,Inc.公司和Pulmatrix,Inc.公司的董事会。McGuire先生还担任麻省理工学院(Massachusetts Institute of Technology)David H.Koch综合癌症研究所的董事会成员,哈佛商学院Arthur Rock创业中心和梦百合倡议咨询委员会以及达特茅斯学院Thayer工程学院顾问委员会。McGuire先生拥有霍巴特学院(Hobart College)的物理学和经济学学士学位,达特茅斯学院(Thayer School at Dartmouth College)的工程学硕士学位和哈佛商学院(Harvard Business School)的工商管理硕士学位。
Terrance McGuire has served as a member of our board of directors since December 2017. Mr. McGuire serves as a General Partner of Polaris Partners, a venture capital firm he co-founded in 1996. He currently serves on the board of directors of Alector, Inc. and Cyclerion, Inc., and previously served on the board of directors of Acceleron Pharma, Inc., Arsanis, Inc., Ironwood Pharmaceuticals, Inc. and Pulmatrix, Inc. Mr. McGuire also serves as a member of the board of The David H. Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology, The Arthur Rock Center for Entrepreneurship at Harvard Business School and The Healthcare Initiative Advisory Board and on the Board of Advisors of the Thayer School of Engineering at Dartmouth College. Mr. McGuire holds a B.S. in Physics and Economics from Hobart College, an M.S. in Engineering from the Thayer School at Dartmouth College and an M.B.A. from Harvard Business School.
Michael Mendelsohn

Michael Mendelsohn自2017年4月以来一直担任我们的董事会成员。Mendelsohn博士也是Cyclerion Pharmaceuticals的董事会成员,他自2019年4月起在该公司任职,并自2016年5月起担任Cardurion Pharmaceuticals的执行主席兼总裁。自2015年4月以来,Mendelsohn博士还一直担任Takeda Pharmaceutical Co.Ltd.首席医疗和科学官的高级顾问和顾问。2014年12月至2018年12月,他担任Ironwood Pharmaceuticals首席科学官兼研究与开发总裁的高级顾问和顾问,以及制药咨询委员会成员。2014年5月至2017年7月,Mendelsohn博士是SV Health Investors的风险合伙人。在此之前,Mendelsohn博士于2010年6月至2013年11月担任默克研究实验室的高级副总裁兼心血管研究全球主管。从1993年到2010年,他曾担任Tufts Medical Center和Tufts University School of Medicine的教员,在那里他曾创立分子心脏病研究所(the Molecular Cardiology Research Institute),并担任执行董事(从1997年到2010年),也曾担任首席科学官(从2008年到2010年)。Mendelsohn博士之前是Brigham and Women&8217;s Hospital和Harvard Medical School心血管学院的成员。Mendelsohn博士在阿默斯特学院(Amherst College)获得学士学位,在哈佛医学院(Harvard Medical School)获得医学博士学位。


Michael Mendelsohn has served as a member of our board of directors since April 2017. Dr. Mendelsohn is also member of the board of directors of Cyclerion Pharmaceuticals, where he has served since April 2019 as well as the Executive Chairman and President of Cardurion Pharmaceuticals, where he has served since May 2016. Since April 2015 Dr. Mendelsohn has also been a senior advisor and consultant to the chief medical and scientific officer of Takeda Pharmaceutical Co. Ltd. From December 2014 to December 2018 he served as senior advisor and consultant and a member of the pharmaceuticals advisory committee for the chief scientific officer and president of research and development at Ironwood Pharmaceuticals. From May 2014 to July 2017 Dr. Mendelsohn was a venture partner for SV Health Investors. Prior to that, from June 2010 to November 2013 Dr. Mendelsohn served as Senior Vice President and Global Head of Cardiovascular Research at Merck Research Laboratories. From 1993 to 2010 Dr. Mendelsohn was a faculty member at Tufts Medical Center and Tufts University School of Medicine, where he founded and was the executive director of the Molecular Cardiology Research Institute from 1997 to 2010 and served as Chief Scientific Officer from 2008 to 2010. Dr. Mendelsohn was previously a member of the cardiovascular faculty at Brigham and Women’s Hospital and Harvard Medical School. Dr. Mendelsohn received a B.A. from Amherst College and M.D. from Harvard Medical School.
Michael Mendelsohn自2017年4月以来一直担任我们的董事会成员。Mendelsohn博士也是Cyclerion Pharmaceuticals的董事会成员,他自2019年4月起在该公司任职,并自2016年5月起担任Cardurion Pharmaceuticals的执行主席兼总裁。自2015年4月以来,Mendelsohn博士还一直担任Takeda Pharmaceutical Co.Ltd.首席医疗和科学官的高级顾问和顾问。2014年12月至2018年12月,他担任Ironwood Pharmaceuticals首席科学官兼研究与开发总裁的高级顾问和顾问,以及制药咨询委员会成员。2014年5月至2017年7月,Mendelsohn博士是SV Health Investors的风险合伙人。在此之前,Mendelsohn博士于2010年6月至2013年11月担任默克研究实验室的高级副总裁兼心血管研究全球主管。从1993年到2010年,他曾担任Tufts Medical Center和Tufts University School of Medicine的教员,在那里他曾创立分子心脏病研究所(the Molecular Cardiology Research Institute),并担任执行董事(从1997年到2010年),也曾担任首席科学官(从2008年到2010年)。Mendelsohn博士之前是Brigham and Women&8217;s Hospital和Harvard Medical School心血管学院的成员。Mendelsohn博士在阿默斯特学院(Amherst College)获得学士学位,在哈佛医学院(Harvard Medical School)获得医学博士学位。
Michael Mendelsohn has served as a member of our board of directors since April 2017. Dr. Mendelsohn is also member of the board of directors of Cyclerion Pharmaceuticals, where he has served since April 2019 as well as the Executive Chairman and President of Cardurion Pharmaceuticals, where he has served since May 2016. Since April 2015 Dr. Mendelsohn has also been a senior advisor and consultant to the chief medical and scientific officer of Takeda Pharmaceutical Co. Ltd. From December 2014 to December 2018 he served as senior advisor and consultant and a member of the pharmaceuticals advisory committee for the chief scientific officer and president of research and development at Ironwood Pharmaceuticals. From May 2014 to July 2017 Dr. Mendelsohn was a venture partner for SV Health Investors. Prior to that, from June 2010 to November 2013 Dr. Mendelsohn served as Senior Vice President and Global Head of Cardiovascular Research at Merck Research Laboratories. From 1993 to 2010 Dr. Mendelsohn was a faculty member at Tufts Medical Center and Tufts University School of Medicine, where he founded and was the executive director of the Molecular Cardiology Research Institute from 1997 to 2010 and served as Chief Scientific Officer from 2008 to 2010. Dr. Mendelsohn was previously a member of the cardiovascular faculty at Brigham and Women’s Hospital and Harvard Medical School. Dr. Mendelsohn received a B.A. from Amherst College and M.D. from Harvard Medical School.
Peter M. Hecht

Peter M. Hecht ,自我们公司于1998年成立开始,他一直担任我们首席执行官和董事。在成立Ironwood之前,他是Whitehead Institute for Biomedical Research的研究人员。他持有Stanford University,的数学学士学位和生物学硕士学位,以及 the University of California at Berkeley的分子生物学哲学博士学位。


Peter M. Hecht has served as our chief executive officer and a director since co-founding the company in 1998 during which he has built a highly respected leadership team and culture that worked together to discover, develop and commercialize LINZESS®, a novel first-in-mechanism therapeutic that quickly became the branded prescription market leader in its class and has been taken by millions of patients for irritable bowel syndrome with constipation and chronic idiopathic constipation. Additionally, the team has pioneered new areas of science, produced a development portfolio with multiple innovative drug candidates, and established a valuable network of global partnerships. Through a combination of private and public equity, structured debt, and partnerships, Dr. Hecht and his team raised over one billion dollars to fund these efforts. Prior to founding Ironwood, Dr. Hecht was a research fellow at Whitehead Institute for Biomedical Research. Dr. Hecht serves on the advisory board of Ariadne Labs. He earned a B.S. in mathematics and an M.S. in biology from Stanford University, and holds a Ph.D. in molecular biology from the University of California at Berkeley.
Peter M. Hecht ,自我们公司于1998年成立开始,他一直担任我们首席执行官和董事。在成立Ironwood之前,他是Whitehead Institute for Biomedical Research的研究人员。他持有Stanford University,的数学学士学位和生物学硕士学位,以及 the University of California at Berkeley的分子生物学哲学博士学位。
Peter M. Hecht has served as our chief executive officer and a director since co-founding the company in 1998 during which he has built a highly respected leadership team and culture that worked together to discover, develop and commercialize LINZESS®, a novel first-in-mechanism therapeutic that quickly became the branded prescription market leader in its class and has been taken by millions of patients for irritable bowel syndrome with constipation and chronic idiopathic constipation. Additionally, the team has pioneered new areas of science, produced a development portfolio with multiple innovative drug candidates, and established a valuable network of global partnerships. Through a combination of private and public equity, structured debt, and partnerships, Dr. Hecht and his team raised over one billion dollars to fund these efforts. Prior to founding Ironwood, Dr. Hecht was a research fellow at Whitehead Institute for Biomedical Research. Dr. Hecht serves on the advisory board of Ariadne Labs. He earned a B.S. in mathematics and an M.S. in biology from Stanford University, and holds a Ph.D. in molecular biology from the University of California at Berkeley.
Marsha H. Fanucci

Marsha H. Fanucci,自2009年起,她一直担任董事。自2004年7月至2009年1月,她担任 Millennium Pharmaceuticals, Inc.的高级副总裁和首席财务官,负责公司战略,财务,财务规划和报表以及运营。在Millennium任职时,她还担任财务和公司战略部门副总裁,以及公司开发和战略部门的副总裁。此前,自1998年至2000年,她是 Genzyme Corporation的公司开发和战略部门的副总裁,这是一个生物技术公司。1987年至1998年,她任职于Arthur D. Little, Inc.,在该公司她最近的是担任副总裁和董事。她目前任职于 Momenta Pharmaceuticals, Inc. 和 Alnylam Pharmaceuticals, Inc.的董事会。她取得了 West Virginia University配药学学士学位,以及Northeastern University。工商管理学硕士学位。


Marsha H. Fanucci has been a member of Forma Therapeutics Holdings, Inc. board of directors since October 2015. Since 2009 Ms. Fanucci has been an independent consultant. From 2004 through 2009 she served as senior vice president and chief financial officer of Millennium Pharmaceuticals, Inc., a biopharmaceutical company that was subsequently acquired by Takeda Pharmaceuticals Company, or Takeda. She previously served in various other roles at Millennium, including as vice president, finance and corporate strategy and vice president, corporate development. Ms. Fanucci is a member of the boards of directors of Alnylam Pharmaceuticals, Inc. and Ironwood Pharmaceuticals, Inc., each a publicly-traded biopharmaceutical company. She previously served as a director of Momenta Pharmaceuticals, Inc., a publicly-traded biopharmaceutical company. Ms. Fanucci received her B.S. in pharmacy from West Virginia University and her M.B.A. from Northeastern University.
Marsha H. Fanucci,自2009年起,她一直担任董事。自2004年7月至2009年1月,她担任 Millennium Pharmaceuticals, Inc.的高级副总裁和首席财务官,负责公司战略,财务,财务规划和报表以及运营。在Millennium任职时,她还担任财务和公司战略部门副总裁,以及公司开发和战略部门的副总裁。此前,自1998年至2000年,她是 Genzyme Corporation的公司开发和战略部门的副总裁,这是一个生物技术公司。1987年至1998年,她任职于Arthur D. Little, Inc.,在该公司她最近的是担任副总裁和董事。她目前任职于 Momenta Pharmaceuticals, Inc. 和 Alnylam Pharmaceuticals, Inc.的董事会。她取得了 West Virginia University配药学学士学位,以及Northeastern University。工商管理学硕士学位。
Marsha H. Fanucci has been a member of Forma Therapeutics Holdings, Inc. board of directors since October 2015. Since 2009 Ms. Fanucci has been an independent consultant. From 2004 through 2009 she served as senior vice president and chief financial officer of Millennium Pharmaceuticals, Inc., a biopharmaceutical company that was subsequently acquired by Takeda Pharmaceuticals Company, or Takeda. She previously served in various other roles at Millennium, including as vice president, finance and corporate strategy and vice president, corporate development. Ms. Fanucci is a member of the boards of directors of Alnylam Pharmaceuticals, Inc. and Ironwood Pharmaceuticals, Inc., each a publicly-traded biopharmaceutical company. She previously served as a director of Momenta Pharmaceuticals, Inc., a publicly-traded biopharmaceutical company. Ms. Fanucci received her B.S. in pharmacy from West Virginia University and her M.B.A. from Northeastern University.

高管简历

中英对照 |  中文 |  英文
Mark G. Currie

MarkG.Currie将在这次离职后担任我们的总裁。Currie博士目前担任Ironwood公司的高级副总裁,首席科学官和研究与开发总裁,自2002年以来一直担任这些职务。在加入Ironwood之前,Currie博士指导心血管和中枢神经系统疾病研究,担任Sepracor Inc.发现研究的Vice President。此前,Currie博士发起、建立并领导了Discovery Pharmaceuticology,还曾担任孟山都公司关节炎和炎症总监。Currie博士在南阿拉巴马大学(University of South Alabama)获得生物学学士学位,并在维克森林大学(Wake Forest University)鲍曼-格雷医学院(Bowman-Gray School of Medicine)获得细胞生物学博士学位。


Mark G. Currie will serve as our President upon completion of this separation. Dr. Currie currently serves as Ironwood's senior vice president, chief scientific officer and president of research and development and has held these positions since 2002. Prior to joining Ironwood, Dr. Currie directed cardiovascular and CNS disease research as vice president of discovery research at Sepracor Inc. Previously, Dr. Currie initiated, built and led discovery pharmacology and also served as director of arthritis and inflammation at Monsanto Company. Dr. Currie earned a B.S. in biology from the University of South Alabama and holds a Ph.D. in cell biology from the Bowman-Gray School of Medicine of Wake Forest University.
MarkG.Currie将在这次离职后担任我们的总裁。Currie博士目前担任Ironwood公司的高级副总裁,首席科学官和研究与开发总裁,自2002年以来一直担任这些职务。在加入Ironwood之前,Currie博士指导心血管和中枢神经系统疾病研究,担任Sepracor Inc.发现研究的Vice President。此前,Currie博士发起、建立并领导了Discovery Pharmaceuticology,还曾担任孟山都公司关节炎和炎症总监。Currie博士在南阿拉巴马大学(University of South Alabama)获得生物学学士学位,并在维克森林大学(Wake Forest University)鲍曼-格雷医学院(Bowman-Gray School of Medicine)获得细胞生物学博士学位。
Mark G. Currie will serve as our President upon completion of this separation. Dr. Currie currently serves as Ironwood's senior vice president, chief scientific officer and president of research and development and has held these positions since 2002. Prior to joining Ironwood, Dr. Currie directed cardiovascular and CNS disease research as vice president of discovery research at Sepracor Inc. Previously, Dr. Currie initiated, built and led discovery pharmacology and also served as director of arthritis and inflammation at Monsanto Company. Dr. Currie earned a B.S. in biology from the University of South Alabama and holds a Ph.D. in cell biology from the Bowman-Gray School of Medicine of Wake Forest University.
William Huyett

William Huyett担任我们的首席运营官。在2017年12月加入Ironwood之前,Huyett先生在麦肯锡公司(McKinsey and Company,Inc.)华盛顿特区,苏黎世和波士顿办事处工作了30年。在McKinsey任职期间,Huyett先生服务于生命科学、工业和其他技术密集型部门的客户。他一直担任McKinsey公司的荣誉高级合伙人(2015年12月以来),此前曾担任高级合伙人(1998年7月至2015年12月)。作为高级合伙人,Huyett先生是公司制药和医疗产品及其战略和公司财务实践的领导者。他也曾任职McKinsey&8217;s Shareholder公司的董事会,也曾担任其财务委员会主席。在加入麦肯锡之前,Huyett先生曾在Allen-Bradley(现为罗克韦尔自动化公司)担任自动化行业的多个线管理职位。Huyett先生是在伦敦证券交易所上市的Georgia梦百合Group plc的董事会非执行主席,也是在伦敦证券交易所上市的Georgia Capital的独立董事。他任职于几个非营利董事会,包括the Rockefeller University、马萨诸塞州伍兹霍尔的海洋生物实验室。他在弗吉尼亚大学(University of Virginia)获得电子工程学士学位和工商管理硕士学位。


William Huyett serves as our chief operating officer. Prior to joining Ironwood in December 2017 Mr. Huyett spent 30 years with McKinsey and Company, Inc., in its Washington D.C., Zurich, and Boston offices. During his tenure at McKinsey, Mr. Huyett served clients in the life sciences, industrial and other technology-intensive sectors. He has been a Senior Partner Emeritus at McKinsey since December 2015 and was previously a Senior Partner from July 1998 to December 2015. As a Senior Partner, Mr. Huyett was a leader in the firm’s pharmaceutical and medical products and its strategy and corporate finance practices. He also served on McKinsey’s Shareholder’s Council its board of directors, serving as chair of its Finance Committee. Prior to joining McKinsey, Mr. Huyett held a variety of line management positions in the automation industry with Allen-Bradley (now Rockwell Automation, Inc.). Mr. Huyett is the non-executive chair of the board of directors of the London Stock Exchange-listed Georgia Healthcare Group PLC and an independent director of the London Stock Exchange-listed Georgia Capital. He serves on several not-for-profit boards, including The Rockefeller University and the Marine Biological Laboratory in Woods Hole, Massachusetts. He earned his B.S. in electronics engineering and his M.B.A. from the University of Virginia.
William Huyett担任我们的首席运营官。在2017年12月加入Ironwood之前,Huyett先生在麦肯锡公司(McKinsey and Company,Inc.)华盛顿特区,苏黎世和波士顿办事处工作了30年。在McKinsey任职期间,Huyett先生服务于生命科学、工业和其他技术密集型部门的客户。他一直担任McKinsey公司的荣誉高级合伙人(2015年12月以来),此前曾担任高级合伙人(1998年7月至2015年12月)。作为高级合伙人,Huyett先生是公司制药和医疗产品及其战略和公司财务实践的领导者。他也曾任职McKinsey&8217;s Shareholder公司的董事会,也曾担任其财务委员会主席。在加入麦肯锡之前,Huyett先生曾在Allen-Bradley(现为罗克韦尔自动化公司)担任自动化行业的多个线管理职位。Huyett先生是在伦敦证券交易所上市的Georgia梦百合Group plc的董事会非执行主席,也是在伦敦证券交易所上市的Georgia Capital的独立董事。他任职于几个非营利董事会,包括the Rockefeller University、马萨诸塞州伍兹霍尔的海洋生物实验室。他在弗吉尼亚大学(University of Virginia)获得电子工程学士学位和工商管理硕士学位。
William Huyett serves as our chief operating officer. Prior to joining Ironwood in December 2017 Mr. Huyett spent 30 years with McKinsey and Company, Inc., in its Washington D.C., Zurich, and Boston offices. During his tenure at McKinsey, Mr. Huyett served clients in the life sciences, industrial and other technology-intensive sectors. He has been a Senior Partner Emeritus at McKinsey since December 2015 and was previously a Senior Partner from July 1998 to December 2015. As a Senior Partner, Mr. Huyett was a leader in the firm’s pharmaceutical and medical products and its strategy and corporate finance practices. He also served on McKinsey’s Shareholder’s Council its board of directors, serving as chair of its Finance Committee. Prior to joining McKinsey, Mr. Huyett held a variety of line management positions in the automation industry with Allen-Bradley (now Rockwell Automation, Inc.). Mr. Huyett is the non-executive chair of the board of directors of the London Stock Exchange-listed Georgia Healthcare Group PLC and an independent director of the London Stock Exchange-listed Georgia Capital. He serves on several not-for-profit boards, including The Rockefeller University and the Marine Biological Laboratory in Woods Hole, Massachusetts. He earned his B.S. in electronics engineering and his M.B.A. from the University of Virginia.
Peter M. Hecht

Peter M. Hecht ,自我们公司于1998年成立开始,他一直担任我们首席执行官和董事。在成立Ironwood之前,他是Whitehead Institute for Biomedical Research的研究人员。他持有Stanford University,的数学学士学位和生物学硕士学位,以及 the University of California at Berkeley的分子生物学哲学博士学位。


Peter M. Hecht has served as our chief executive officer and a director since co-founding the company in 1998 during which he has built a highly respected leadership team and culture that worked together to discover, develop and commercialize LINZESS®, a novel first-in-mechanism therapeutic that quickly became the branded prescription market leader in its class and has been taken by millions of patients for irritable bowel syndrome with constipation and chronic idiopathic constipation. Additionally, the team has pioneered new areas of science, produced a development portfolio with multiple innovative drug candidates, and established a valuable network of global partnerships. Through a combination of private and public equity, structured debt, and partnerships, Dr. Hecht and his team raised over one billion dollars to fund these efforts. Prior to founding Ironwood, Dr. Hecht was a research fellow at Whitehead Institute for Biomedical Research. Dr. Hecht serves on the advisory board of Ariadne Labs. He earned a B.S. in mathematics and an M.S. in biology from Stanford University, and holds a Ph.D. in molecular biology from the University of California at Berkeley.
Peter M. Hecht ,自我们公司于1998年成立开始,他一直担任我们首席执行官和董事。在成立Ironwood之前,他是Whitehead Institute for Biomedical Research的研究人员。他持有Stanford University,的数学学士学位和生物学硕士学位,以及 the University of California at Berkeley的分子生物学哲学博士学位。
Peter M. Hecht has served as our chief executive officer and a director since co-founding the company in 1998 during which he has built a highly respected leadership team and culture that worked together to discover, develop and commercialize LINZESS®, a novel first-in-mechanism therapeutic that quickly became the branded prescription market leader in its class and has been taken by millions of patients for irritable bowel syndrome with constipation and chronic idiopathic constipation. Additionally, the team has pioneered new areas of science, produced a development portfolio with multiple innovative drug candidates, and established a valuable network of global partnerships. Through a combination of private and public equity, structured debt, and partnerships, Dr. Hecht and his team raised over one billion dollars to fund these efforts. Prior to founding Ironwood, Dr. Hecht was a research fellow at Whitehead Institute for Biomedical Research. Dr. Hecht serves on the advisory board of Ariadne Labs. He earned a B.S. in mathematics and an M.S. in biology from Stanford University, and holds a Ph.D. in molecular biology from the University of California at Berkeley.
Mark G. Currie

Mark G. Currie,自2002年加入Ironwood Pharmaceuticals, Inc.开始,他一直担任Ironwood Pharmaceuticals, Inc.的高级副总裁,首席科学馆和研究与开发部门总裁。在加入Ironwood之前,他指导心血管和中枢神经系统疾病的研究,担任Sepracor Inc.研发部门的副总裁。此前,他在Monsanto Company开始建造和领导药理学研究,还是关节炎和炎症方面的主管。他取得了 the University of South Alabama的生物学学士学位,以及 the Bowman-Gray School of Medicine of Wake Forest University。的细胞生物学哲学博士学位。


Mark G. Currie has served as president and chief scientific officer of Cyclerion Therapeutics, Inc. since April 2019 and previously served as senior vice president, chief scientific officer and president of R&D at Ironwood Pharmaceuticals, Inc. from 2002 to April 2019.Prior to joining Ironwood, Dr. Currie directed cardiovascular and central nervous system disease research as vice president of discovery research at Sepracor, Inc.Previously, Dr. Currie initiated, built and led discovery pharmacology and also served as director of arthritis and inflammation at Monsanto Company.Dr. Currie earned a B.S. in biology from the University of South Alabama and holds a Ph.D. in cell biology from the Bowman-Gray School of Medicine of Wake Forest University.
Mark G. Currie,自2002年加入Ironwood Pharmaceuticals, Inc.开始,他一直担任Ironwood Pharmaceuticals, Inc.的高级副总裁,首席科学馆和研究与开发部门总裁。在加入Ironwood之前,他指导心血管和中枢神经系统疾病的研究,担任Sepracor Inc.研发部门的副总裁。此前,他在Monsanto Company开始建造和领导药理学研究,还是关节炎和炎症方面的主管。他取得了 the University of South Alabama的生物学学士学位,以及 the Bowman-Gray School of Medicine of Wake Forest University。的细胞生物学哲学博士学位。
Mark G. Currie has served as president and chief scientific officer of Cyclerion Therapeutics, Inc. since April 2019 and previously served as senior vice president, chief scientific officer and president of R&D at Ironwood Pharmaceuticals, Inc. from 2002 to April 2019.Prior to joining Ironwood, Dr. Currie directed cardiovascular and central nervous system disease research as vice president of discovery research at Sepracor, Inc.Previously, Dr. Currie initiated, built and led discovery pharmacology and also served as director of arthritis and inflammation at Monsanto Company.Dr. Currie earned a B.S. in biology from the University of South Alabama and holds a Ph.D. in cell biology from the Bowman-Gray School of Medicine of Wake Forest University.